miR-217-5p NanomiRs Inhibit Glioblastoma Growth and Enhance Effects of Ionizing Radiation via EZH2 Inhibition and Epigenetic Reprogramming
<b>Background/Objectives</b>: CSCs are critical drivers of the tumor and stem cell phenotypes of glioblastoma (GBM) cells. Chromatin modifications play a fundamental role in driving a GBM CSC phenotype. The goal of this study is to further our understanding of how stem cell-driving events control changes in chromatin architecture that contribute to the tumor-propagating phenotype of GBM. <b>Methods</b>: We utilized computational analyses to identify a subset of clinically relevant genes that were predicted to be repressed in a Polycomb repressive complex 2 (PRC2)-dependent manner in GBM upon induction of stem cell-driving events. These associations were validated in patient-derived GBM neurosphere models using state-of-the-art molecular techniques to express, silence, and measure microRNA (miRNA) and gene expression changes. Advanced Poly(β-amino ester) nanoparticle formulations (PBAEs) were used to deliver miRNAs in vivo to orthotopic human GBM tumor models. <b>Results</b>: We show that glioma stem cell (GSC) formation and tumor propagation involve the crosstalk between multiple epigenetic mechanisms, resulting in the repression of the miRNAs that regulate PRC2 function and histone H3 lysine 27 tri-methylation (H3K27me3). We also identified miR-217-5p as an EZH2 regulator repressed in GSCs and showed that miR-217-5p reconstitution using advanced nanoparticle formulations re-activates the PRC2-repressed genes, inhibits GSC formation, impairs tumor growth, and enhances the effects of ionizing radiation in an orthotopic model of GBM. <b>Conclusions</b>: These findings suggest that inhibiting PRC2 function by targeting EZH2 with miR-217-5p advanced nanoparticle formulations could have a therapeutic benefit in GBM.
Authors
- Karen Smith-Connor
- Jordan J. Green (ORCID: https://orcid.org/0000-0003-4176-3808)
- Stephany Y. Tzeng (ORCID: https://orcid.org/0000-0002-7561-482X)
- Sophie Sall (ORCID: https://orcid.org/0009-0001-4234-4077)
- Yuan Rui (ORCID: https://orcid.org/0000-0001-5165-8898)
- Weiqiang Zhou (ORCID: https://orcid.org/0000-0001-9396-9571)
- Amanda Johnson (ORCID: https://orcid.org/0000-0002-3055-945X)
- Hernando López-Bertoni (ORCID: https://orcid.org/0000-0001-6618-1092)
- Jack Korleski (ORCID: https://orcid.org/0000-0003-3845-7869)
- John Laterra (ORCID: https://orcid.org/0000-0002-2983-5365)
- Bachchu Lal
- Christopher Caputo
- Sweta Sudhir (ORCID: https://orcid.org/0000-0002-0741-7138)
- Harmon Singh Khela (ORCID: https://orcid.org/0000-0002-1962-3844)
- Yunqing Li (ORCID: https://orcid.org/0000-0002-9679-505X)
- Tanmaya Madhvacharyula
- Anisha Rasamsetty
Institutions
- Kennedy Krieger Institute (US)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- WinnMed (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-30
- DOI
- https://doi.org/10.3390/cancers17010080
- Citations
- 1
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Johns Hopkins University
- Sidney Kimmel Comprehensive Cancer Center
- National Cancer Institute